Title of Invention

A TRANSITION METAL COMPOUND CONTAINING A CYCLIC ORGANIC LIGAND

Abstract

According to the present invention there is provided a compound in the form of a transition metal compound including a transition metal, a phosphorus containing ligand, and a cyclic organic ligand. The phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound. The cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bound. The invention also relates to a method preparing such a compound and a metathesis reaction wherein such a compound is used as a catalyst.

Full Text

The invention relates to the use of a phosphorus containing ligand and a cyclic organic ligand in a transition metal compound and to the use of a phosphorus containing ligand and cyclic organic ligand in a catalysed reaction, preferably a metathesis reaction. The invention also relates to a compound including such a phosphorus containing ligand and cyclic organic ligand; and to a metathesis reaction using the said catalyst. The invention further relates to a method of preparing such a catalyst. There is considerable interest regarding the formation of carbon-carbon bonds via olefin metathesis. Olefin metathesis refers to the metal-catalysed redistribution of carbon-carbon double bonds. Cross metathesis (CM) can be described as a metathesis reaction between two non-cyclic olefins, which may be the same or different, for example: Where the olefins are the same, the reaction is known as self metathesis. Ring-opening metathesis polymerization (ROMP) is a variant of olefin metathesis reactions wherein cyclic olefins (for example) produce polymers and co-polymers, for example: Ring-closing metathesis (RCM) represents a process in which an acyclic diene (for example) is cyclised to produce a cycloalkene, for example; As indicated above metathesis reactions take place in the presence of a catalyst. A great deal of research has been done in an attempt to synthesise and isolate catalysts which are able to catalyse homogeneous olefin metathesis reactions. More particularly the synthesis of Group VIII transition metal metathesis catalysts has led to catalysts with increased functional group tolerance and stability with respect to conditions such as air, water and acids. During the 1990's the so-called "1st generation Grubbs catalyst" of formula 1a was developed: This well defined ruthenium catalyst afforded high selectivities, high reaction rates and good tolerance for oxygenates in feed during homogeneous olefin metathesis reactions, including cross metathesis, ring closing metathesis and ring opening metathesis polymerisation. These processes have many potential commercial applications for the commodities, pharmaceutical and fine chemicals industries as well as in the field of speciality polymers. Several reviews describe the development and applications of Grubbs-type catalysts (for example Ace. Chem. Res. 2001, 34, 18-24; Angew. Chem., Int .Ed., 2000, Much research has been carried out to investigate the effect of changing the nature of the ligands, (for example J. Am. Chem. Soc. 1997, 119, 3887 -3897; Tetrahedron Lett. 1999, 40, 2247-2250; Angew. Chem., Int. Ed. 1998, 37, 2490-2493) resulting in the development of second generation Grubbs catalysts. The main thrust of second generation Grubbs catalyst research has related to a move away from the use of phosphine ligands to the use of highly nucleophilic N-heterocyclic carbenes for homogeneous metathesis reactions. Formula 1b shows the structure of the standard second generation Grubbs catalyst. While this catalyst shows greater reactivity compared to catalyst 1a, it is more expensive than the first generation catalyst. WO ZA03/00087 discloses the use of a phosphorus containing ligand as a ligand for a metathesis catalyst in a catalysed metathesis reaction wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound. A major disadvantage of complexes depicted by formula 1a relates to their preparation which requires either reagents which are hazardous (e. g. potentially explosive diazoalkanes), or difficult to prepare (e.g. diphenylcyclopropene), or extremely sensitive. As a result there exists a need to develop efficient routes to these complexes where 1. The individual components (ligands and alkylidene) are inexpensive, non-hazardous and scaleable 2. The reaction to prepare the Ru-alkylidene-type olefin metathesis catalyst that uses the individual components as reagents is straight forward, non-hazardous and can be performed on the multi-kilogram scale economically. It has now been found that relatively inexpensive phosphorus containing ligands such as phosphabicylononane ligands, when combined with a specific alkylidene-type moiety such as the indenylidene alkylidene moiety provide a non-hazardous, economical Ru-alkylidene-type olefin metathesis catalysts. These catalysts or catalyst precursors are usually easy to prepare from well accessible, stable and essentially non-toxic starting materials and can usually be isolated and stored. At least some of these catalysts exhibit high catalytic activity, a good compatibility with functional groups, solvents, water and additives, and they need not to be activated by any additive. An indenylidene ruthenium complex was first synthesized by Hill (J. Chem. Soc.Dalton Trans. 1999, 285), who incorrectly assigned the structure of the diphenylallenylidene complex. Together with Furstner the complex was used in various ring-closing metathesis reactions (Chem. Commun. 1999,601-602). Later detailed evaluations showed that the correct structure is the rearranged indenylidene complex {Organometallics 1999, 18, 5416-5419, Chem. Eur. J. 2001, 7, 4811-4820). Still, this complex was only used in RCM by Furstner in the synthesis of natural products. In 2003 F. Verpoort published the use of this complex in the Atom Transfer Radical Addition (ATRA), New J. Chem. 2003, 27, 257-262. Several different olefins have been used in the ATRA with carbon tetrachloride in good to nearly quantitative yields. Verpoort also used the complex in the nucleophilic addition of carboxylic acids to terminal alkynes {Synlett 2002, 935-941), e.g. formic acid, acetic acid, isovaleric acid, or benzoic acid to t-Butylacetylene, 1,7-octadiyne or 4-pentynoic acid. Here the catalyst showed moderate yields. Blechert (Synlett 2001, 3, 430-432) used the catalyst as a precursor for other metathesis catalysts. The indenylidene complexes as described above did not include a phosphorus containing ligand which is a heterocyclic organic compound with a ligating phosphorous atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound. SUMMARY OF THE INVENTION According to a first aspect of the present invention there is provided the use of a phosphorus containing ligand and a cyclic organic ligand as ligands for a catalyst in the form of a transition metal compound containing a transition metal; wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phophorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound; and wherein the cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bond. Preferably the catalyst is a metathesis catalyst. According to a second aspect of the present invention there is provided the use of a phosphorus containing ligand and a cyclic organic ligand in the preparation of a transition metal compound catalyst including a transition metal, the phosphorus containing ligand and the cyclic organic ligand; wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound; and wherein the cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bond. Preferably the catalyst is for use in a metathesis reaction. According to a third aspect of the present invention there is provided a compound in the form of a transition metal compound including a transition metal, a phosphorus containing ligand, and a cyclic organic ligand; wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound; and wherein the cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bound. Preferably the compound is a catalyst, and preferably the catalyst is a metathesis catalyst. Preferably the metathesis reaction/catalyst is a homogenous metathesis reaction/catalyst, or a reaction with an immobilized preformed catalyst. Preferably the ligating phosphorus atom is also bound to a further moiety which is not part of the heterocyclic ring structure. Preferably the phosphorus containing ligand comprises a phosphine ligand, preferably a secondary or tertiary phosphine ligand, preferably a tertiary phosphine ligand. The further moiety bound to the ligating phosphorus atom may be an atom, and preferably it is H. In an alternative and preferred embodiment of the invention the said moiety may comprise an organic group, preferably an organyl group. The organyl group may comprise an alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkynyl and optionally it may be substituted. Preferably it comprises an alkyl, cycloalkyl or aryl. Preferably the heterocyclic organic compound has a single heteroatom in the form of the ligating phosphorus atom. The heterocyclic organic compound may comprise a bicyclic organic compound. Preferably the heterocyclic organic compound includes no unsaturated carbon to carbon bonds. Preferably the two ring structures have at least 3 shared atoms. Preferably the two ring structures do not have more than 12 ring atoms, preferably they have nine ring atoms. In a preferred embodiment of the invention the phosphine ligand comprises a bicyclic tertiary phosphine having a ligating phosphorus atom which is preferably bound to two first atoms (preferably carbon atoms) in the ring structure with each of said first atoms being bound to two other second atoms (preferably carbon atoms) in the ring structure. Preferably both the second atoms are carbon atoms. It will be appreciated that in this embodiment each first atom is bound to three ring atoms. In a preferred embodiment of the invention the heterocyclic organic compound comprises a phosphacycloalkane, preferably a phosphabicycloalkane, preferably a phosphabicyclononane, each of which optionally may be substituted. Preferably it comprises a monophosphacycloalkane, preferably a monophosphabicycloalkana, preferably a monophosphabicyclononane. Preferably the compound comprises a tertiary phosphine. In a preferred embodiment of the invention, the phosphabicyclononane is a 9-phosphabicyclo[3.3.1]nonane of formula 2a or a 9-phosphabicyclo[4.2.1] nonane of formula 2b or mixtures thereof: wherein R1 is H or an organic group (including an organyl group). Preferably R1 is an optionally substituted alkyl, or optionally substituted aryl, or an optionally substituted cycloalkyl. The phosphabicyclononane may be a compound of formula 2a. In one embodiment of the invention R1 is alkyl, preferably -C20H41 also known as eicosyi. in this instance the ligand is known as eicosyl pfioban (that is for both compounds of formula 2a and 2b where R1 is -C2oH41). In one preferred embodiment of the invention R1 is cyclohexyl, In this instance the ligand is known as cyclohexyl phoban (that is for both compounds of formula 2a and 2b where R1 is cyclohexyl). The cyclic ring structure of the cyclic organic ligand may be a heterocyclic ring structure, but preferably it is a homocyclic ring structure. The ring structure which includes the ligating carbon atom may be saturated, but preferably it is unsaturated. The ring structure including the ligating carbon atom may be monocyclic, but preferably it is polycyclic and preferably it includes at least two fused ring structures, that is two ring structures that share two adjacent ring atoms. In one embodiment of the invention the ligating carbon atom may form part of a non-aromatic ring structure which is fused to an aromatic (including heteroaromatic) ring structure. The non-aromatic ring structure may include only carbon ring atoms and preferably it has only 5 ring atoms. The non-aromatic ring structure may include at least one (preferably two) unsaturated carbon-carbon bonds. The non-aromatic ring structure may include at least one non-hydrogen moiety bound to a carbon atom of the non-aromatic ring structure which non-hydrogen moiety does not form part of the aromatic ring structure. The non-hydrogen moiety may comprise an organic group, preferably an organyl group, preferably it comprises an aromatic or heteroaromatic group and preferably it is phenyl. The aromatic ring structure fused to the non-aromatic ring structure may contain more ring atoms than the non-aromatic ring structure, and preferably if it has 6 ring atoms. The aromatic ring structure may include only carbon ring atoms. In one embodiment of the invention the cyclic organic ligand may comprise indenylidene or a substituted derivative thereof. The transition metal may comprise a Group VIII metal, preferably 0$ or Ru, preferably Ru. The catalyst may include further ligands as defined below. The metathesis reaction may comprise cross-metathesis (including self metathesis and ethenolysis), ring-opening polymerisation metathesis, ring-closing metathesis, or acyclic diene metathesis. According to another aspect of the present invention there is provided a compound of formula 3 wherein M is a transition metal; L1 is a neutral electron donor ligand; L2 is a phosphorus containing ligand in the form of a heterocyclic organic compound with a ligating phosphorus atom which ligates with M, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound; X1 and X2 are independently a ligand; and Z is a cyclic organic ligand in the form of a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with M by means of a double bond. The transition metal M may be a transition metal as described earlier above, and preferably it is Ru. Preferably the compound is a catalyst, preferably a metathesis catalyst, and preferably a homogeneous metathesis catalyst. Ligand L1 L1 may be selected from the group consisting of a phosphine, sulfonated phosphine, phosphite, phosphinite, phosphonite, arsine, stibine, amine, amide, imine, nitrosyl, carbene and pyridine. In a preferred embodiment of the invention L1 may be any neutral phosphine ligand or carbene ligand. Preferably L1 is a phosphine preferably a phosphine of the formula PR3R4R5, wherein R3, R4 and R5 are each independently an organic group, preferably an organyl group, preferably aryl, C1 - C10kyl or cycloalkyl. Preferably L1 is selected from the group consisting of -P(cyclohexyl)3; -P(cyclopentyl)3; -P(iso-propyl)3; and -P(phenyl)3. Preferably L1 comprises a phosphorus containing ligand as defined in respect of L2. Accordingly L1may be the same as L2. In another embodiment of the invention L1 may be selected from a group of heterocyclic compounds containing substituted or unsubstituted five membered rings which may be saturated or unsaturated and which may include at least two adjacent or non adjacent nitrogen ring atoms. Examples of such ligands are illustrated as formulas 4, 5 and 6: wherein R and R may be any group such as H, an organic group (including an organyl group, preferably alkyl, aryl, cycloalkyl, adamantyl or the like, and may be further substituted with functional groups). L2 is a phosphorus containing ligand as already defined with reference to formula(3). Preferably, the phosphorus containing ligand comprises a phosphine ligand, preferably a secondary or tertiary phosphine ligand, preferably a tertiary phosphine ligand. The ligating phosphorus atom may also be bound to a further moiety which is not part of the heterocyclic ring structure. The further moiety bound to the ligating phosphorus atom may be an atom, and preferably it is H. In an alternative and preferred embodiment of the invention the said moiety may comprise an organic group, preferably an organyl group. The organyl group may comprise an alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkyenyl and optionally it may be substituted. Preferably it comprises an alkyl, cycloalkyl or aryl. Preferably the heterocyclic organic compound has a single heteroatom in the form of the ligating phosphorus atom. The heterocyclic organic compound may comprise a bicyclic organic compound. Preferably the heterocyclic organic compound includes no unsaturated carbon to carbon bonds. Preferably the two ring structures have at least 3 shared atoms. Preferably the two ring structures do not have more than 12 ring atoms, preferably they have nine ring atoms. In a preferred embodiment of the invention the phosphine ligand comprises a bicyclic tertiary phosphine having a ligating phosphorus atom which is preferably bound to two first atoms (preferably carbon atoms) in the ring structure with each of said first atoms being bound to two other second atoms (preferably carbon atoms) in the ring structure. Preferably both the second atoms are carbon atoms. It will be appreciated that in this embodiment each first atom is bound to three ring atoms. In a preferred embodiment of the invention the heterocyclic gfganiG GQmpQUnd comprises a phosphacycloalkane, preferably a phosphabicycloalkane, preferably a phosphabicyclononane, each of which optionally may be substituted. Preferably it comprises a monophosphacycloalkane, preferably a monophosphabicycloalkane, preferably a monophosphabicyclononane. Preferably the compound comprises a tertiary phosphine. In a preferred embodiment of the invention, the phosphabicyclononane is a 9-phosphabicyclo-[3.3.1]nonane of formula 2a or a 9-phosphabicyclo[4.2.1] nonane of formula 2b or mixtures thereof: wherein R1 is H, or an organic group (including an organyl group). Preferably R1 is an optionally substituted alkyl, or optionally substituted aryl, or an optionally substituted cycloalkyl. In one embodiment of the invention R1 is alkyl, preferably -C2oH41also known as eicosyl. In this instance the ligand is known as eicosyl phoban (that is for both compounds of formula 2a and 2b where R1 is -C2oH41. In one preferred embodiment of the invention R1 is cyclohexyl. In this instance the ligand is known as cyclohexyl phoban (that is for both compounds of formula 2a and 2b where R1 is cyclohexyl. Liaands X1 and X2 X1 and X2 may be independently selected from the group consisting of hydrogen; halide; C1- C20 alkyl; aryl; Co - C20 alkoxide; aryloxide; C3- C2o alkyldiketonate; aryldiketonate; C1- C20 carboxylate; arylsulfonate; Ci - C20 alkylsulfonate; C1- C20 alkylthiol; aryl thiol; C1- C20 alkylsulfonyl; and C1-C20 alkylsulfinyl, the compound being optionally substituted with one or more other moieties selected from the group consisting of C1- C10 alkyl; C1- C10 alkoxy; aryl and halide. Preferably X1 and X2are each independently selected from the group consisting of halide; CF3C02, CH3C02,; CFH2C02; (CH3)3C0; (CF3)2(CH3)CO; (CF3)(CH3)2CO; PhO; MeO; EtO; tosylate; mesylate; and trifluoromethanesulfonate. Preferably X1 and X2 are each independently an anionic ligand, preferably a halide. Preferably X1 and X2 are each chloride. Ligand Z Z, the cyclic organic ligand, may be as described above. In some cases some of the ligands X1, X2, L1, L2 and Z may be linked to each other. In one preferred embodiment of the invention, the compound of formula 3 may be a compound and of formula 7: wherein L1, L2, X1 and X2 are as defined above; and each of Y1, Y11, Y1", Y,V, YV and YVI is independently H or a moiety other than H, including an organic group (preferably an organyl group), and at least some of Y1 to Yvl may be linked to each other. In one preferred embodiment of the invention the compound of formula 7 may be a compound of formula (8) wherein X1, X2, L1 and I2 are as defined above. In another preferred embodiment of the invention the compound of formula 7 may be a compound of formula 8a: wherein L1, L2, X1 and X2 are as defined above; and Xa to X' are independently hydrogen or a moiety other than H, (preferably halogen, N02, OR, SR or NR2) provided that at least one of Xa to X' is not H. According to another aspect of the invention there is provided the use of a catalyst as described hereinbefore including a catalyst of formula 3, in a metathesis reaction, preferably a homogeneous metathesis reaction. The reaction is preferably a reaction of at least one olefinic compound in the form of an olefin with one or more double bonds or a compound which includes an olefinic moiety with one or more double bonds. The reaction conditions for the metathesis reaction wherein th.9 catalyst is ussd may be in accordance io conditions which are well known to a person skilled in the art of metathesis reactions. Preferably the olefinic compound has a single double bond in the case of a cross-metathesis reaction. Preferably the olefinic compound has two double bonds in the case of a ring-closing metathesis reaction. Preferably the olefinic compound is a cyclic olefin in the case of a ring-opening metathesis polymerisation reaction. According to a further aspect of the invention there is provided a metathesis product produced by a metathesis reaction using a catalyst substantially as described hereinabove. The metathesis catalyst may be a catalyst of formula 3 hereinbefore, preferably a homogeneous metathesis catalyst. According to yet a further aspect of the invention there is provided a catalysed metathesis reaction wherein at least one olefinic compound in the form of an olefin with one or more double bonds or a compound which includes an olefinic moiety with one or more double bonds is subjected to metathesis in the presence of a catalyst of the type described hereinbefore. Preferably the metathesis reaction is a homogeneous metathesis reaction. According to yet a further aspect of the invention there is provided a process for a ring closing metathesis reaction in the presence of a catalyst of the type described hereinbefore. According to yet a further aspect of the invention there is provided a process for a ring opening metathesis polymerization reaction in the presence of a catalyst of the type described hereinbefore. According to yet a further aspect of the invention there is provided a process for a cross or self metathesis reaction in the presence of a catalyst of the type described hereinbefore. The cross metathesis reaction may specifically be an ethenolysis reaction (where one of the two olefinic compounds is ethylene). The metathesis reactions preferably comprise homogeneous metathesis reactions. The process may include the step of forming the catalyst in situ. The process may then include the steps of adding together of a source of a transition metal; a source of a phosphorus containing ligand in the form of a heterocyclic organic compound with a ligating phosphorous atom suitable for ligating with the transition metal in the source of the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound; a source of a cyclic organic ligand in the form of a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which is suitable to ligate with the transition metal in the source of the transition metal by means of a double bond; and at least one olefinic compound to be metathesised which olefinic compound is an olefin or a compound which includes an olefinic moiety. The source of transition metal may be a source of Ru, and preferably it is an inorganic salt of ruthenium such as RuCl3.xH20. According to another aspect of the present invention there is provided a method of preparing a compound of formula 3 by reacting a compound of formula 9 with a source of L1 and a source of L2, where L1 and L2 are as defined above: wherein M, X1, X2 and Z are as defined with reference to formula 3; and Lx and Ly are the same or different, each is a neutral ligand, and each of Lx and Ly is not the same as L1 or L2. It will be appreciated that L1 and I2 may be the same and accordingly the source thereof may be the same. Preferably the compound of formula 9 is a compound of formula 10 wherein X1, X2, Lxand Ly are as defined above; and each of Y1, Y", Y1", Y!V, YV and YVI is independently H or a moiety other than H, including an organic group (preferably an organyl group), and at least some of Y1 to YVI may be linked to each other. Preferably the compound of formula 10 is a compound of formula 11. wherein X1, X2, Lx and Ly are as defined above. Preferably the compound of formula 10 is a compound of formula 12 wherein X1, X2, Lx, Ly are as defined above; and Xa to Xj are independently hydrogen or a moiety other than H, (preferably halogen, N02) OR, SR or NR2) provided that at least one of Xa to X' is not H. In a preferred embodiment Lx and Ly are identical and each is triphenylphosphine. It will be appreciated that the above reaction of preparing a compound of formula 3 is a ligand exchange reaction. The method of preparation may also include the step of preparing the compounds of formula 9, 10, 11 or 12 and the ligand exchange reaction may be performed in situ after preparation of the compound of formula 9,10,11 or The compound of formula 9 (preferably formulae 10 to 12) may be prepared from reacting a compound consisting of Ru, X1, X2, L* and Ly only, only with a source of Z. Such a compound consisting of Ru, X1, X2, Lx and Ly only may be a phosphine-ruthenium-halide complex, preferably a phosphine-ruthenium-chloride complex, preferably (PPh3)3 RuCI2 or (PPh3)4 Ru CI2. This reaction may be carried out in a polar organic solvent. The resulting compound may be subjected to one or more ligand exchange reactions. The source of Z may be an alcohol. The compound consisting of Ru, X1, X2, Lxand Ly only may be prepared by reacting a ruthenium halide (preferably a ruthenium chloride) compound with a source of Lx, Ly and also a source of X1 and X2 where X1 and X2 are not halide. Preferably the reaction is between ruthenium chloride and PPh3 only. The reaction may be carried out in a solvent, preferably an organic solvent, preferably a alcohol, preferably ethanol. A compound of formula 7, preferably of formula 8, may also be prepared by reaction of a rutliQnium-cli-halido-bis-aryl-dimdr Mmpta, preferably [(P- cymene)RuCl2]2, with two ligands chosen from L*, Ly, L1 or L2 as defined above, and a di-aryl-propargylic alcohol, preferably 2,2-diphenyl-alkin-1-ol in an organic solvent, preferably followed by exchange of one or two ligands of type L*, Ly, L1 or L2 with one or two other ligands of type L*, Ly, L1 or L2, followed by isolation of the desired complex through standard procedures. Without thereby limiting the scope of the invention it will now be further described with reference to the following non-limiting examples. In a 50 mL round-bottom flask was added Ru(PPh3)3Cl2 (1.0 g, 1.04 mmol) and 1,1-diphenyl-2-propyn-1-ol (330 mg, 1.59 mmol) followed by degassed tetrahydrofuran (80 mL). The mixture was refluxed for 2 h and then the solvent was removed under reduced pressure. Cyclohexylphoban (ca. 3.1 mixture of [3.3.1] and [4.2.1] isomers, 672 mg, 3 mmol) in CH2CI2 (20 mL) was added, and the mixture stirred for 24 h. After such time the solvent was removed and the residue taken up in hexane. The solid thus formed was sonicated for 10 minutes and stirred (or for 1 hour then filtered to give the desired complex (12). 31P(1H) NMR (121 MHz, C6D6): 5 = 22.0 (bs); 'H NMR (300 MHz, C6D6): 5 = 8.25 (s, 1H,), 7.80-6.75 (m, 9H), 2.80 (s, 4H. PCH of Phoban), 2.26-0.40 (m, 46H, Phoban H). Single crystals suitable for X-ray diffraction were obtained by recrystalization from evaporation of an ether solution. A crystal structure was obtained (below): C43H60CL2RU, Mf = 810.82, monoclinic, space group P2(1)/c, a = 22.336(9), b = 17.602(7), c = 9.796(4) A, V = 3834(3) A3, T = 173(2) K, Z = 4, Acaicd = 1-357 gem'3, SMART diffractometer.51939 reflections collected, 6839 unique [R(in,) = 0.1491], R1 = 0.1137, wR2 = 0.2231. Methyl oleate (99%) was purchased from Aldrich and passed through a short (2 cm) pad of alumina before use. In a 50 mL stainless-steel autoclave fitted with dip-tube for sampling was charged methyl oleate (12 g, 40.0 mmol). Tetradecane (2.5 g, internal standard) was added and the catalyst (12) of example 1 (0.010 mmol) was weighed and transferred into a Schlenk flask under argon. Toluene (5 mL, degassed) was added to the Schlenk flask and an aliquot (1 mL) of this stock solution was transferred to the autoclave. The autoclave was pressurized (4-20 bar (400 to 2000 kPa) of ethylene) and heated via computerized temperature controller to the desired temperature. Samples were taken at regular intervals using a dip-tube apparatus, and analyzed by GC with an MDN column. The results below in figure 1 show the productive turonover obtained using catalyst (12) (S/C = 10 000:1) at 10 bar ethylene pressure at various Metathesis using complex (12) in the self-metathesis of 1-Decene A 250 mL three-necked round bottom flask was fitted with a reflux condenser, thermometer and septum. A needle was inserted through the septum and connected to a gas supply via a needle valve to ensure a slow and steady stream of argon through the reaction solution. 1-Decene (24 mL, 0.127 mol) was added to the reaction vessel and the reaction was heated to 65 °C. The catalyst (12) of example 1 (11.0 mg, 0.014 mmol) was weighed into a custom-made aluminum weighing tray and added to the reaction mixture. Samples were taken at regular intervals via syringe through the septum. Samples were analysed by GC with a Pona column. The results below in figure 2 show the % conversion obtained using catalyst (12) at 65 °C. It will be appreciated that catalyst (12) was easy to prepare from well accessible, stable and essentially non-toxic starting materials and the catalyst can be isolated and stored. The catalyst exhibited a high catalytic activity, a good compatibility with functional groups and solvents and it need not be activated by any additive. It will be appreciated that complex a can be used for a variety of metathesis reactions and it will be appreciated that many variations in detail are possible without thereby departing from the spirit and scope of the invention. WE CLAIM: 1. A transition metal compound of formula 3 wherein M is ruthenium; L1 is a phosphorus containing ligand in the form of a phosphabicyclononane wherein the phosphabicyclononane is a 9-phosphabicyclo-[3.3.1]nonane of formula 2a or a 9-phosphabicycfo[4.2.1] nonane of formula 2b or mixtures thereof: wherein R1 is an alkyl or cycloalkyt group; or L1 is selected from the group consisting of -P(cydohexyl)3; -P(cyclopentyl)3; -P(iso-propyl)3; and -P(phenyl)3, or L1 is a carbene ligand selected from the group of heterocyclic five membered rings illustrated by formulas 4,5 and 6: wherein R"" and R"" are alkyl, aryl, cycloalkyl or adamantly groups; l_2 is a phosphorus containing ligand in the form of a phosphabicyclononane wherein the phosphabicyclononane is a 9-phosphabicyclo-[3.3.1]nonane of formula 2a or a 9-phosphabicyclo[4.2.1 ] nonane of formula 2b or mixtures thereof: wherein R1 is an alkyl or cycloalkyl group;. s X1 and X2 are independently a halide; and Z is a cyclic organic ligand in the form of a phenyl-substituted indenylidene ligand. 2. The compound as claimed in claim 1 wherein L1 and L2 are the same. 3. The compound as claimed in claim 1 or 2, wherein the compound of formula 3 is a compound of formula 8 wherein X1, X2, L1 and L2 are as defined in claim 1. 4. A catalysed metathesis reaction wherein at least one olefinic compound in the form of an olefin with one or more double bonds or a compound which includes an olefinic moiety with one or more double bonds is subjected to metathesis in the presence of a catalyst in the form of a compound as claimed in claim 1. 5. The reaction as claimed in claim 4 which is a homogeneous metathesis reaction. 6. The reaction of either one of claims 4 or 5 wherein the catalyst is formed in situ. 7. A method of preparing a compound of formula 3 as set out in claim 1 by reacting a compound of formula 9 with a source of L1 and a source of L2, wherein L1 and L2 is as defined in claim 1 wherein M, X1, X2 and Z are as defined with reference to formula 3 in claim 1; and Lx and LY are the same, each being a neutral triphenylphosphine ligand. 8. The compound as claimed in claim 1, wherein some of the ligands X1, X2, L1, L2 and Z are linked to each other. 9. The compound as claimed in claim 1, wherein R1 is an eicosyl or a cyclohexl group. ABSTRACT Title: A transition metal compound containing a cyclic organic ligand According to the present invention there is provided a compound in the form of a transition metal compound including a transition metal, a phosphorus containing ligand, and a cyclic organic ligand. The phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound. The cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bound. The invention also relates to a method preparing such a compound and a metathesis reaction wherein such a compound is used as a catalyst.

Documents:

00678-kolnp-2008-abstract.pdf

00678-kolnp-2008-claims.pdf

00678-kolnp-2008-correspondence others.pdf

00678-kolnp-2008-description complete.pdf

00678-kolnp-2008-form 1.pdf

00678-kolnp-2008-form 2.pdf

00678-kolnp-2008-form 3.pdf

00678-kolnp-2008-form 5.pdf

00678-kolnp-2008-international publication.pdf

00678-kolnp-2008-international search report.pdf

678-KOLNP-2008-(16-05-2013)-CORRESPONDENCE.pdf

678-KOLNP-2008-(16-05-2013)-OTHERS PCT FORM.pdf

678-KOLNP-2008-(18-04-2013)-ABSTRACT.pdf

678-KOLNP-2008-(18-04-2013)-ANNEXURE TO FORM 3.pdf

678-KOLNP-2008-(18-04-2013)-CLAIMS.pdf

678-KOLNP-2008-(18-04-2013)-CORRESPONDENCE.pdf

678-KOLNP-2008-(18-04-2013)-DESCRIPTION (COMPLETE).pdf

678-KOLNP-2008-(18-04-2013)-FORM-1.pdf

678-KOLNP-2008-(18-04-2013)-FORM-2.pdf

678-KOLNP-2008-(18-04-2013)-FORM-5.pdf

678-KOLNP-2008-(18-04-2013)-OTHERS.pdf

678-KOLNP-2008-(18-04-2013)-PETITION UNDER RULE 137.pdf

678-KOLNP-2008-ASSIGNMENT.pdf

678-KOLNP-2008-CANCELLED PAGES.pdf

678-KOLNP-2008-CORRESPONDENCE 1.1.pdf

678-KOLNP-2008-CORRESPONDENCE 1.2.pdf

678-KOLNP-2008-CORRESPONDENCE 1.3.pdf

678-KOLNP-2008-CORRESPONDENCE OTHERS 1.1.pdf

678-KOLNP-2008-EXAMINATION REPORT.pdf

678-kolnp-2008-form 18.pdf

678-KOLNP-2008-FORM 26 1.1.pdf

678-KOLNP-2008-FORM 26.pdf

678-KOLNP-2008-FORM 6.pdf

678-KOLNP-2008-GRANTED-ABSTRACT.pdf

678-KOLNP-2008-GRANTED-CLAIMS.pdf

678-KOLNP-2008-GRANTED-DESCRIPTION (COMPLETE).pdf

678-KOLNP-2008-GRANTED-FORM 1.pdf

678-KOLNP-2008-GRANTED-FORM 2.pdf

678-KOLNP-2008-GRANTED-FORM 3.pdf

678-KOLNP-2008-GRANTED-FORM 5.pdf

678-KOLNP-2008-GRANTED-SPECIFICATION-COMPLETE.pdf

678-KOLNP-2008-INTERNATIONAL PUBLICATION.pdf

678-KOLNP-2008-INTERNATIONAL SEARCH REPORT & OTHERS.pdf

678-KOLNP-2008-OTHERS 1.1.pdf

678-KOLNP-2008-OTHERS.pdf

678-KOLNP-2008-PA.pdf

678-KOLNP-2008-REPLY TO EXAMINATION REPORT.pdf